# Section_V_Demographics_Complete_Data_Sources.xlsx

## Sheet: Cat vs Dog Trends

| The Global Feline Shift: Cat vs. Dog Population Trends (2020-2025)       | Unnamed: 1      | Unnamed: 2      | Unnamed: 3     | Unnamed: 4     | Unnamed: 5      | Unnamed: 6      |
|:-------------------------------------------------------------------------|:----------------|:----------------|:---------------|:---------------|:----------------|:----------------|
| nan                                                                      | nan             | nan             | nan            | nan            | nan             | nan             |
| Year                                                                     | USA Dogs (M HH) | USA Cats (M HH) | China Dogs (M) | China Cats (M) | Europe Cats (M) | Europe Dogs (M) |
| 2020                                                                     | 67.5            | 45.3            | 55             | 58             | nan             | nan             |
| 2021                                                                     | 67.8            | 45.8            | 54.3           | 62             | nan             | nan             |
| 2022                                                                     | 68              | 46.2            | 53.5           | 65.5           | nan             | nan             |
| 2023                                                                     | 68.2            | 46.5            | 53             | 69             | 108             | 90              |
| 2024                                                                     | 68              | 47.5            | 52.6           | 71.5           | nan             | nan             |
| 2025                                                                     | 68              | 49              | nan            | nan            | nan             | nan             |
| Key Insights:                                                            | nan             | nan             | nan            | nan            | nan             | nan             |
| • USA: Cats +5.4% (2023-2025), Dogs stable                               | nan             | nan             | nan            | nan            | nan             | nan             |
| • China 2024: Historic tipping point - Cats overtake dogs for first time | nan             | nan             | nan            | nan            | nan             | nan             |
| • Europe 2023: 108M cats vs. 90M dogs (cat-dominant continent)           | nan             | nan             | nan            | nan            | nan             | nan             |

## Sheet: Senior Pet Growth

| Senior Pet Population Growth: The Demographic Tsunami (2020-2030E)   | Unnamed: 1               | Unnamed: 2               | Unnamed: 3   |
|:---------------------------------------------------------------------|:-------------------------|:-------------------------|:-------------|
| nan                                                                  | nan                      | nan                      | nan          |
| Year                                                                 | Senior Dogs (% of total) | Senior Cats (% of total) | Status       |
| 2020                                                                 | 45                       | 48                       | Historical   |
| 2021                                                                 | 46                       | 49                       | Historical   |
| 2022                                                                 | 48                       | 51                       | Historical   |
| 2023                                                                 | 50                       | 52                       | Historical   |
| 2024                                                                 | 52                       | 54                       | Current      |
| 2025                                                                 | 54                       | 56                       | Projection   |
| 2026                                                                 | 56                       | 57                       | Projection   |
| 2027                                                                 | 57                       | 58                       | Projection   |
| 2028                                                                 | 58                       | 59                       | Projection   |
| 2029                                                                 | 59                       | 60                       | Projection   |
| 2030                                                                 | 60                       | 61                       | Projection   |
| nan                                                                  | nan                      | nan                      | nan          |
| Key Insights:                                                        | nan                      | nan                      | nan          |
| • USA 2024: 52% senior dogs, 54% senior cats (age 7+)                | nan                      | nan                      | nan          |
| • Europe: 30% senior pets, 33% have underlying health conditions     | nan                      | nan                      | nan          |
| • Projection 2030: 60%+ senior pets globally                         | nan                      | nan                      | nan          |
| • Senior pets = 3.6x higher nutraceutical spend                      | nan                      | nan                      | nan          |

## Sheet: Global Pet Population

| Global Pet Population by Region (2025)       | Unnamed: 1                | Unnamed: 2                        |
|:---------------------------------------------|:--------------------------|:----------------------------------|
| nan                                          | nan                       | nan                               |
| Region                                       | Pet Population (Millions) | Notes                             |
| APAC                                         | 300                       | High growth, urbanization         |
| Europe                                       | 281.5                     | 108M cats, 90M dogs (FEDIAF 2025) |
| North America                                | 200                       | Value growth, mature market       |
| Latin America                                | 200                       | Volume growth, Brazil 160M        |
| Middle East                                  | 50                        | Emerging market                   |
| Africa                                       | 30                        | Early stage                       |
| TOTAL                                        | 1061.5                    | 1 Billion+ pets globally          |
| Total Addressable Market:                    | nan                       | nan                               |
| • 1.06 Billion pets globally                 | nan                       | nan                               |
| • $50B+ nutraceutical TAM at $50/pet average | nan                       | nan                               |

## Sheet: Ownership Penetration

| Pet Ownership Penetration: Growth Runway Analysis                       | Unnamed: 1                | Unnamed: 2               |
|:------------------------------------------------------------------------|:--------------------------|:-------------------------|
| nan                                                                     | nan                       | nan                      |
| Country/Region                                                          | Household Penetration (%) | Growth Potential         |
| USA                                                                     | 71                        | Mature (benchmark)       |
| Mexico                                                                  | 70                        | High penetration         |
| Europe Average                                                          | 49                        | Moderate                 |
| Romania                                                                 | 45                        | Above EU average         |
| Japan                                                                   | 38                        | Aging population         |
| China (Urban)                                                           | 20                        | 3.5x growth to US levels |
| nan                                                                     | nan                       | nan                      |
| Key Insight:                                                            | nan                       | nan                      |
| • China at 20% vs. US at 71% = 3.5x growth runway if convergence occurs | nan                       | nan                      |

## Sheet: Chronic Care Market

| Chronic Care Nutraceutical Market Share by Function                                  | Unnamed: 1       | Unnamed: 2   | Unnamed: 3      |
|:-------------------------------------------------------------------------------------|:-----------------|:-------------|:----------------|
| nan                                                                                  | nan              | nan          | nan             |
| Functional Category                                                                  | Market Share (%) | CAGR (%)     | Growth Status   |
| Joint & Mobility                                                                     | 31.2             | 4            | Mature          |
| Gut Health & Zootechnical                                                            | 28               | 6            | High Growth     |
| Preventive Wellness (Pre-Senior)                                                     | 12               | 7            | High Growth     |
| Skin & Coat                                                                          | 10               | 3.5          | Mature          |
| Immune Support                                                                       | 8                | 5            | Moderate        |
| Cognitive Support (CDS)                                                              | 8                | 7.5          | Fastest Growing |
| Other                                                                                | 2.8              | 3            | Mature          |
| nan                                                                                  | nan              | nan          | nan             |
| Key Insights:                                                                        | nan              | nan          | nan             |
| • Cognitive Support: Fastest-growing (7.5% CAGR) driven by pets living past 12 years | nan              | nan          | nan             |
| • Pre-Senior (ages 5-7): $8B untapped preventive wellness opportunity                | nan              | nan          | nan             |
| • Ingredients: MCTs, homotaurine, L-carnitine for cognitive dysfunction              | nan              | nan          | nan             |

## Sheet: Ingredient Evolution

| Joint Health Ingredient Evolution: From Generic to Premium (2020 vs. 2025)   | Unnamed: 1       | Unnamed: 2                | Unnamed: 3    |
|:-----------------------------------------------------------------------------|:-----------------|:--------------------------|:--------------|
| nan                                                                          | nan              | nan                       | nan           |
| 2020 Market Share                                                            | nan              | nan                       | nan           |
| Ingredient                                                                   | Market Share (%) | Efficacy                  | Price Premium |
| Glucosamine                                                                  | 60               | Low evidence              | Baseline      |
| Chondroitin                                                                  | 25               | Low evidence              | Baseline      |
| Other                                                                        | 15               | Various                   | Various       |
| nan                                                                          | nan              | nan                       | nan           |
| 2025 Market Share                                                            | nan              | nan                       | nan           |
| Ingredient                                                                   | Market Share (%) | Efficacy                  | Price Premium |
| Glucosamine                                                                  | 35               | Low evidence (declining)  | Baseline      |
| UC-II Collagen                                                               | 20               | Clinically backed         | 3x premium    |
| Omega-3                                                                      | 15               | Anti-inflammatory         | 2x premium    |
| Chondroitin                                                                  | 15               | Low evidence              | Baseline      |
| Green-Lipped Mussel                                                          | 10               | Natural anti-inflammatory | 2.5x premium  |
| Other                                                                        | 5                | Various                   | Various       |
| nan                                                                          | nan              | nan                       | nan           |
| Key Insights:                                                                | nan              | nan                       | nan           |
| • UC-II Collagen: 25% CAGR, products like Rejensa® gaining market acceptance | nan              | nan                       | nan           |
| • Shift to efficacy-based ingredients = 40% margin expansion opportunity     | nan              | nan                       | nan           |
| • Glucosamine declining due to recent reviews showing low efficacy           | nan              | nan                       | nan           |

## Sheet: Life Stage Spend

| Life Stage Spend Curve: Annual Nutraceutical Spend per Pet      | Unnamed: 1   | Unnamed: 2       | Unnamed: 3                                |
|:----------------------------------------------------------------|:-------------|:-----------------|:------------------------------------------|
| nan                                                             | nan          | nan              | nan                                       |
| Life Stage                                                      | Age Range    | Annual Spend ($) | Key Products                              |
| Puppy/Kitten                                                    | 0-1 year     | 50               | Growth, immunity                          |
| Adult                                                           | 1-5 years    | 80               | Maintenance                               |
| Pre-Senior (NEW)                                                | 5-7 years    | 120              | Preventive wellness, healthspan extension |
| Senior                                                          | 7-12 years   | 180              | Joint health, cognitive support           |
| Geriatric                                                       | 12+ years    | 250              | Palliative care, quality of life          |
| nan                                                             | nan          | nan              | nan                                       |
| Key Insights:                                                   | nan          | nan              | nan                                       |
| • Pre-Senior Market (5-7 years): $8B untapped opportunity       | nan          | nan              | nan                                       |
| • Preventive wellness = healthspan extension (delaying frailty) | nan          | nan              | nan                                       |
| • Senior/Geriatric: 3.6x higher spend vs. adult pets            | nan          | nan              | nan                                       |
| • Fastest-growing life stage: Pre-senior preventive care        | nan          | nan              | nan                                       |

## Sheet: Sources & Citations

| Complete Data Sources & Citations for Section V                                | Unnamed: 1        | Unnamed: 2                                                   | Unnamed: 3                                              |
|:-------------------------------------------------------------------------------|:------------------|:-------------------------------------------------------------|:--------------------------------------------------------|
| nan                                                                            | nan               | nan                                                          | nan                                                     |
| Source                                                                         | Type              | Specific Data Provided                                       | URL/Reference                                           |
| APPA National Pet Owners Survey 2025                                           | Primary           | USA: 94M HH (71%), 68M dogs, 49M cats, senior pet %          | https://www.americanpetproducts.org                     |
| FEDIAF Facts & Figures 2025                                                    | Primary           | Europe: 281.5M pets, 108M cats, 90M dogs, 49% HH penetration | https://fediaf.org/facts-figures                        |
| China Pet Industry White Paper 2024                                            | Primary           | China: 71.5M cats, 52.6M dogs, 2024 tipping point            | Published annually by Pethadoop                         |
| AVMA (American Veterinary Medical Association)                                 | Primary           | Senior pet statistics, veterinary care data                  | https://www.avma.org/resources-tools/reports-statistics |
| Japan Pet Food Association                                                     | Regional          | 75% small dogs (<10kg), urbanization impact                  | https://www.petfood.or.jp                               |
| Euromonitor International                                                      | Market Research   | Market sizing, CAGR projections, regional analysis           | Subscription database                                   |
| Grand View Research                                                            | Market Research   | Functional segment market share, ingredient trends           | https://www.grandviewresearch.com                       |
| Mordor Intelligence                                                            | Market Research   | Chronic care market analysis, growth rates                   | https://www.mordorintelligence.com                      |
| UC-II Collagen Clinical Studies                                                | Scientific        | Efficacy data for joint health ingredients                   | Published peer-reviewed studies                         |
| MCT Cognitive Studies                                                          | Scientific        | Medium-chain triglycerides for cognitive dysfunction         | Veterinary neuroscience journals                        |
| Industry Surveys (Proprietary)                                                 | Primary           | Life stage spend, humanization index, multispecies HH        | Pet industry associations                               |
| Rejensa® Product Data                                                          | Commercial        | Market acceptance of UC-II based joint supplements           | Manufacturer data                                       |
| Global Pet Industry Magazine                                                   | News/Data         | Trends, M&A, market dynamics                                 | https://globalpetindustry.com                           |
| Pet Food Industry Magazine                                                     | Trade Publication | Ingredient evolution, formulation trends                     | https://www.petfoodindustry.com                         |
| nan                                                                            | nan               | nan                                                          | nan                                                     |
| Methodology Notes:                                                             | nan               | nan                                                          | nan                                                     |
| • All market share and CAGR data: Triangulated from multiple sources           | nan               | nan                                                          | nan                                                     |
| • Projections: Based on historical trends and demographic analysis             | nan               | nan                                                          | nan                                                     |
| • Life stage spend: Derived from industry surveys and veterinary practice data | nan               | nan                                                          | nan                                                     |
| • Updated data: FEDIAF 2025 (Europe 281.5M), APPA 2025 (USA 49M cats)          | nan               | nan                                                          | nan                                                     |

